Variants of human TRAIL (hTRAIL) and human CD95L (hCD95L), encompassing the TNF homology domain (THD), interact with the corresponding receptors and stimulate CD95 and TRAILR2 signaling after cross-linking. The murine counterparts (mTRAIL, mCD95L) showed no or only low receptor binding and were inactive/poorly active after cross-linking. The stalk region preceding the THD of mCD95L conferred secondary aggregation and restored CD95 activation in the absence of cross-linking. A corresponding variant of mTRAIL, however, was still not able to activate TRAIL death receptors, but gained good activity after cross-linking. Notably, disulfide-bonded fusion proteins of the THD of mTRAIL and mCD95L with a subdomain of the tenascin-C (TNC) oligomerization domain, which still assembled into trimers, efficiently interacted with their cognate cellular receptors and robustly stimulated CD95 and TRAILR2 signaling after secondary cross-linking. Introduction of the TNC domain also further enhanced the activity of THD encompassing variants of hTRAIL and hCD95L. Thus, spatial fixation of the N-terminus of the THD appears necessary in some TNF ligands to ensure proper receptor binding. This points to yet unanticipated functions of the stalk and/or transmembrane region of TNF ligands for the functionality of these molecules and offers a broadly applicable option to generate recombinant soluble ligands of the TNF family with superior activity. Ligands of the tumor necrosis factor (TNF) family fulfill crucial roles in the immune system, but have also been implicated in the development of epithelial and endothelial structures. 1 TNF family ligands are primarily expressed as trimeric type II transmembrane proteins and are often processed into soluble variants that are also organized as trimers.
Ligands of the tumor necrosis factor (TNF) family fulfill crucial roles in the immune system, but have also been implicated in the development of epithelial and endothelial structures. 1 TNF family ligands are primarily expressed as trimeric type II transmembrane proteins and are often processed into soluble variants that are also organized as trimers.
1,2 Although shedding of some TNF ligands does not interfere with their capability to activate their corresponding receptors and might be even important for their physiological function, other TNF ligands become inactivated by proteolytic processing. 2 Soluble TNF ligands that are not or only poorly active still interact with their cognate receptors. For example, the soluble forms of TNF, CD95L, TRAIL, and CD40L interact with TNFR2, CD95, TRAILR2, and CD40, respectively, but do not or only poorly activate signaling by these receptors. [3] [4] [5] [6] Notably, inactive or poorly active soluble TNF ligands can be converted into highly active molecules by artificially increasing their avidity. For example, soluble flag-tagged variants of TNF, CD95L, TRAIL, and CD40L stimulate robust signaling by TNFR2, CD95, TRAILR2, and CD40, respectively, provided they were cross-linked with the Flag-specific mAb M2. Likewise, hexameric and dodecameric fusion proteins of soluble CD95L and soluble CD40L as well as non-specifically aggregated preparations of TNF ligands produced in E. coli display high activity. [6] [7] [8] The structural hallmark of the ligands of the TNF family is the carboxy-terminal 'TNF homology domain', which is part of both the transmembrane and soluble forms of TNF ligands. [1] [2] The TNF homology domains (THDs) of the various TNF ligands are composed of a framework of aromatic and hydrophobic residues that adopt an almost identical tertiary fold and cause self association into trimers. [1] [2] The THD also mediates receptor binding. In general, trimeric ligands of the TNF family bind to three molecules of their corresponding receptor(s). This interaction alone is not necessarily sufficient to activate receptor-associated intracellular signaling pathways. Several lines of evidence suggest that the initial formation of trimeric signaling competent ligand receptor complexes is followed by secondary multimerization into supramolecular clusters. [9] [10] [11] These two steps in TNF receptor activation (1. ligand binding; 2. secondary aggregation of receptor ligand complexes) depend to a varying extent on several factors including lipid raft localization, cytoskeleton support, receptor auto-aggregation, receptor associated adapter proteins, but also on affinity and avidity of the ligand receptor interaction and the way how the ligand is presented to the receptor (membrane ligand or immobilized ligand versus soluble ligand, trimers versus higher aggregates).
Here we show that soluble variants of murine CD95L (mCD95L) and murine TRAIL (mTRAIL), solely containing the THD in contrast to their human counterparts, practically do not bind to their corresponding receptors. In accordance with the observed differences in receptor binding, the human, but not the murine ligands, strongly activated CD95 and TRAILR2 after secondary cross-linking. Importantly, fusion proteins of the murine ligands with a small domain of tenascin-C (TNC), forming disulfide bridge-connected trimers, did not aggregate secondarily, but displayed restored receptor binding and strong cross-linking-dependent receptor activation. The activity of secondarily aggregated human TRAIL (hTRAIL) and human CD95L (hCD95L) were also further enhanced by fusion with the TNC domain. Thus, we identified enforced covalent trimerization as a powerful means to increase the activity and stability of some members of the TNF ligand family.
Results and Discussion
Soluble variants of mCD95L and mTRAIL are practically inactive even after cross-linking. Amino terminally Flag-tagged variants of human and murine CD95L and TRAIL containing the THD (aa 137-281 of hCD95L, aa 137-279 of mCD95L, aa 95-291 of hTRAIL, aa 99-291 of mTRAIL) were transiently produced in HEK293 cells and purified from the supernatants by affinity chromatography on anti-flag mAb M2 agarose (Figure 1 and 2a) . Both FlaghCD95L (137-281) and Flag-mCD95L (137-279) migrated in SDS-PAGE analysis as intense doublets with deduced Figure 1 Domain architecture of the various CD95L and TRAIL variants used in this study. TNC,trimerization domain of chicken TNC (aa 110-139), Flag,Flag epitope (DYKDDDDK). The stalk region refers to the structural less defined part between the transmbembrane domain and the TNF homolgy domain of the various ligands molecular masses between 24 and 30 kDa. In addition, a minor fraction of both proteins also migrated at 21 kDa (Figure 2a) . These values significantly exceed the calculated mass of 17 kDa for both Flag-hCD95L(137-281) and FlagmCD95L(137-279). The heterogeneity and discrepancy between calculated and observed molecular mass is in Figure 2 Soluble variants of mCD95L and mTRAIL encompassing solely the THD are practically inactive. (a) Soluble, N-terminally Flag-tagged variants of hCD95L (Flag-hCD95L(137-281)), mCD95L (Flag-mCD95L(137-279)), hTRAIL (Flag-hTRAIL(95-291)), and mTRAIL (Flag-mTRAIL(99-291)) encompassing the THD were produced in HEK293 cells, purified by M2 affinity chromatography and analyzed by SDS-PAGE and silver staining. Migration positions of molecular mass markers (in kDa) are indicated on the left margin. (b) KB cells (human origin), L929 (murine origin), and mCD95-expressing MBL2 transfectants (murine origin) were seeded in triplicates in 96-well plates. The next day, cells (KB, L929) were sensitized for cell death induction by treatment with 2.5 mg/ml CHX and were then stimulated (KB, L929, MBL2-CD95) with the indicated concentrations of Flag-mCD95L(137-279) (KB, MBL2-CD95), Flag-hCD95L(137-281) (KB, MBL2-CD95), Flag-hTRAIL(95-291) (KB, L929), and Flag-mTRAIL(99-291) (KB, L929) in the presence and absence of anti-Flag mAb M2 (CD95L variants: 0.5 mg/ml; TRAIL variants 3 mg/ml). Cell viability was determined by crystal violet staining. (c) Jurkat cells were challenged in triplicates in 96-well plates with the indicated concentration of Flag-hTRAIL(95-291) or M2-crosslinked Flag-hTRAIL(95-291). Cell viability was determined using the MTT assay Enforced covalent trimerization D Berg et al good accordance with the fact that CD95L can be glycosylated at three asparagine residues in the THD, since one N-linked carbohydrate accounts for 2-3 kDa by SDS-PAGE. 12 Flag-hCD95L(137-281) poorly killed human KB cells and murine MBL2-CD95 transfectants cells (ED 50 41000 ng/ml), but readily killed both cell lines after secondary cross-linking via its Flag-tag (ED 50 ¼ 0.1-1 ng/ml). In contrast, the corresponding Flag-tagged mCD95L(137-279) variant practically induced cell death in neither KB nor in MBL2-CD95 cells despite cross-linking (Figure 2b) . A related activity pattern was observed with human and mTRAIL. Both molecules induced less than 25% killing on L929 cells, even at concentrations of 1000 ng/ml. While Flag-hTRAIL(95-291) significantly induced cell death in these cells with 1 ng/ml after secondary cross-linking via the Flag-tag contained in the molecule, Flag-mTRAIL(99-291) was approximately 50-fold less active after secondary aggregation (Figure 2b) . Further, Flag-hTRAIL(95-291) killed KB cells without crosslinking, starting at concentrations of 10 ng/ml, while noncrosslinked Flag-mTRAIL(99-291) showed no activity at all up to 1000 ng/ml (Figure 2b ). Cross-linking with anti-Flag further enhanced the activity of the hTRAIL variant and also allow killing by the murine counterpart at higher concentrations (Figure 2b ). The differential effect of noncrosslinked hTRAIL on KB and L929 cells can be explained by earlier findings demonstrating that TRAILR2 is much more better activated by secondary cross-linked trimers of soluble TRAIL than by non-crosslinked molecules, whereas TRAILR1 is stimulated with the same efficiency by crosslinked and non-crosslinked TRAIL. 5, 13, 14 Thus, in KB cells that express TRAILR1 and TRAILR2, non-crosslinked TRAIL trimers already significantly induce cell death via the TRAILR1, whereas TRAILR1-mediated cell death is not relevant in the murine L929 cell line, because in mice only a homolog of human TRAILR2 exists. 15, 16 In fact, in human Jurkat cells, which express only TRAILR2, noncrosslinked Flag-hTRAIL(95-291) is also practically inactive (Figure 2c ).
The THD of mCD95L and mTRAIL is not sufficient to allow receptor binding. Next, we analyzed binding of the various recombinant ligands to cells using FACS analysis. KB, MBL2-CD95, and L929 cells were incubated with increasing concentrations of the TRAIL and CD95L variants on ice and after removal of unbound molecules, cell associated ligands were detected using anti-Flag mAb M2 and a PE-labeled secondary antibody. Significant binding of Flag-hCD95L(137-281) to human and murine CD95 was observed down to concentrations of 0.3 and 0.1 mg/ml and significant binding of Flag-hTRAIL(95-291) to human and mTRAIL receptors was observed starting with concentrations of 40 and 600 ng/ml, respectively. In contrast, murine CD95L showed no binding even when concentrations upto 5 or 10 mg/ml were used and mTRAIL exerted only weak binding on L929 cells and no binding on KB cells (Figure 3a) . Binding of the murine ligands were also not significantly changed when they were preincubated with the M2 antibody before FACS staining (data not shown). To exclude the possibility that the Flag-tag, which is highly charged, specifically prevented receptor binding of Flag-tagged proteins, we also analyzed a non-tagged variant of mCD95L (Figure 3b ). Owing to the lack of the Flag epitope, we were unable to analyze receptor binding of mCD95L(137-279) directly by FACS. Instead, we performed a competition assay, in which the capacity of the non-tagged ligand to protect against cell death induction was determined using a highly active hexameric fusion protein of hCD95L (Fc-hCD95L) and the Fc domain of human IgG1 (see Holler et al. 7 ) was determined. While preincubation of KB cells with 50 ng/ml Flag-hCD95L(137-281) was sufficient to rescue about half of the cells from Fc-hCD95L-induced cell death, the non-tagged mCD95L(137-279) failed even at high concentrations (1 mg/ml) to show a protective effect (Figure 3c ). We also performed surface plasmon resonance analysis, using an immobilized chimeric protein consisting of the extracellular domain of human CD95 fused to the constant region of human IgG1 and Flag-hCD95L(137-281), Flag-mCD95L Figure 4a ). Thus, there was no evidence from the cross-linking experiments for a differential capability of murine and human ligands to organize into trimers. In gel filtration experiments, Flag-hCD95L(137-281) was eluted in one symmetric peak, which corresponds in size to a molecular mass of about 72 kDa (Table 1, Figure 4b ) in good agreement with a trimeric organization of the glycosylated molecule in solution. The hCD95L preparation obtained after gel filtration still interacted with CD95 and showed normal activity after secondary cross-linking (data not shown). Flag-mCD95L(137-279) was eluted in a highmolecular-weight (MW) peak, a second peak with an elution volume comparable to that of Flag-hCD95L(137-281) trimers (85 kDa) and a third peak corresponding in size to a monomer (31 kDa) ( Figure 4b ). As expected Flag-mCD95L (137-279) derived of each of these peaks was inactive even after cross-linking with the anti-Flag mAb M2 (Table 1) . Thus, the high-molecular-weight Flag-mCD95L(137-279) fractions obviously represented misfolded inactive ligand aggregates rather than activated secondary aggregates of latently active ligand trimers. A similar picture emerged when the various TRAIL variants were analyzed by gel filtration. In all cases, there was a peak corresponding in size to MWs of 75-125 kDa Figure 4b ). In addition, we did also observe a second high MW peak containing inactive TRAIL aggregates (Table 1) . Flag-mTRAIL(99-291) was further found in an additional peak, corresponding in size roughly to a monomer.
Covalent stabilization of the trimeric structure of mCD95L and mTRAIL restores receptor binding and cross-linking-dependent activity. So far our data demonstrated that the trimerization of the THD alone is not necessarily sufficient to ensure proper receptor binding. This suggests that especially in the case of mCD95L and mTRAIL additional structural cues located outside of the THD are required to enable these molecules to bind their cognate receptors. In this regard, the THDs of CD95L and TRAIL are separated from their transmembrane domains by a stalk region. In fact, Nagata and co-workers have shown that a variant of mCD95L (named WX1) comprising aa 101-279 and thus containing the stalk region is biologically active. 17 It is note worthing, Flag-mCD95L(WX1) is already active without secondary cross-linking and organizes to about 50% in oligomers instead of trimers ( Table 1 WX1 variant (named S1) showed also significant activity, which could be further moderately increased by secondary cross-linking (Table 1 Figure 1 and 5b). The specific activity of cross-linked Flag-hCD95L(S1) was roughly 100-fold lower compared to cross-linked Flag-hCD95L(137-281) (Figure 5b) . A chimeric ligand of the stalk region of mCD95L and the THD of hCD95L showed also a significant crosslinking independent capability to stimulate CD95 (Figure 5c ). Flag-mTRAIL(43-291), a soluble mTRAIL variant containing the stalk region, showed a significant, but in comparison to Flag-hTRAIL(114-291) poor capability to induce cell death (Figure 5d ). Of course, membrane mTRAIL was also able to stimulate TRAIL receptor signaling (Figure 5e ). Together, these data suggest that the stalk region contained in some members of the TNF family, for example murine CD95L, has a ligand specific capability to facilitate the formation of secondary aggregated trimers. The different bioactivity of soluble ligand variants with and without stalk region might be explained by the concept that amino acids located outside the THD are required to make contact to their corresponding receptors, but it appeared also possible that the THD of mTRAIL and mCD95L already contained latently all structural information required for receptor binding, but needed in addition spatial fixation and stabilization of their trimeric structure. In fact, a difference between soluble trimeric TRAIL and CD95L and their highly active membranebound counterparts is that the N terminus of the THD in the soluble molecules is practically free, whereas in the membrane-bound ligands the N-terminal part of the THD is fixed by the transmembrane domain and/or the stalk region.
To elucidate whether the improper receptor binding of stalkless mCD95L and mTRAIL trimers was related to insufficient stability and spatial fixation of the THD of these molecules, we generated fusion proteins of these ligands in which the flexibility of the N termini was constrained by fusion to a small protein domain from chicken TNC forming covalently bound compact trimers (Figure 1 ). 18 The TNC trimerization domain was chosen due to its small size of about only 30 aa. 18 Anti-Flag affinity-purified TNC-Flag-mTRAIL(99-291) and Flag-TNC-mCD95L(137-279) migrated both in nonreducing SDS-PAGE analysis as trimers and showed in gel filtration analysis a comparable elution volume than the 20 ml of the various M2 agarose purified proteins were fractionated by gel filtration using a BioSep-SEC-S2000 (300 Â 7.8) column (all CD95L variants, Flag-hTRAIL, Flag-TNC-hTRAIL) or a BioSep-SEC-S2000 (300 Â 7.8) column (Flag-mTRAIL and Flag-TNC-mTRAIL). The columns were calibrated with thyroglobulin (669 kDa), apoferritin (443 kDa), b-amylase (200 kDa), serum albumin (66 kDa), carbonic anhydrase (29 kDa) and cytochrome c (12.4 kDa). The molecular masses corresponding to the elution volumes of the various peaks were calculated using the linear regression of the logarithm of the molecular masses of the standards against their elution volume. Peaks were collected and analyzed as indicated with respect to the presence of the corresponding ligand by Western blot or ELISA, to binding and cell death induction in KB or L929 cells. The peak areas were automatically calculated by the FPLC software and indicate the relative amount of protein contained in the peak. To determine the capacity of proteins in the various peaks to induce cell death, the corresponding samples were titrated on CHX sensitized KB cells. The fold dilution sufficient to induced 50% killing was indicated. n.d. not determined. HWA, high molecular weight aggregates.
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corresponding molecules without TNC domain ( Figure 4a and 6a and Table 1 ). These data showed first that the TNC part within the fusion proteins is still able to form disulfide bonds and indicated secondly that the serial arrangement of the trimerization domains of TNC and TNF ligands still results in the formation of trimers without evidence for a significant formation of high-MW aggregates. In further accordance with a trimeric organization of the TNC-fusion proteins and a lack of secondary aggregation, we detected after chemical cross-linking with increasing concentrations of the homobifunctional cross-linker BS 3 preferentially dimers and trimers (Figure 4a) . Thus, the THD of mCD95L and mTRAIL, irrespective of having a TNC domain or not, organizes into trimers. However, with respect to their functional properties the molecules behaved quite differently. As shown in Figure 3 Flag-mCD95L (137-279) and Flag-mTRAIL(99-291) did not or only poorly interact with their cognate cellular receptors, but the TNC-fusion proteins showed effective binding in FACS analysis and resembled in this regard their human counterparts (Figure 6b and 3a) . Moreover, the murine TNC-fusion proteins are practically inactive despite receptor binding, but stimulated CD95 and TRAIL death receptor signaling after secondary cross-linking with high efficiency (Figure 6c) . To exclude the possibility that the improved receptor binding of the TNC variants is caused by the more distant position of the Flag epitope in TNCmCD95L(137-281) and Flag-TNC-mTRAIL(99-291) relative to the THD domain, rather than by the presence of the TNC domain, we generated ligand variants (Flag-L-mCD95L (137-279) and Flag-L-mTRAIL(99-291)) in which the Flag epitope was separated from the THD of the molecules via a linker corresponding in length to the TNC domain. We found that these ligand variants showed no (Flag-L-mCD95L(137-279)) or only weak activity (Flag-L-mTRAIL(99-291)) without cross-linking. This suggests that the position of the Flag-tag relative to the THD domain of murine ligands has no major relevance for receptor binding of these molecules (Figure 6d ). As the TNC domain is sufficient to recover the receptor binding capacity of the THD of mCD95L and mTRAIL, it is unlikely that specific amino acids located achieved by the TNC domain and (ii) secondary aggregation of THD trimers enabling CD95 activation, a function not achieved by the TNC domain. However, the functions fulfilled by the stalk region are dependent on the ligand regarded and might be realized in concert with the transmembrane domain. For example, the stalk region of hCD95L is dispensable for receptor binding, but mediates to some extent secondary aggregation and the stalk region of mTRAIL seems to stabilize the THD comprising trimer, but does not overcome the need of secondary aggregation for receptor activation.
Fusion proteins of the trimerization domain of TNC and the THD of hTRAIL or hCD95L display higher activity than their TNC less counterparts. To test whether spatial fixation of the THD also improves receptor binding and activity of soluble variants of hTRAIL (Flag-hTRAIL(95-291)) and hCD95L (Flag-hCD95L(137-281)), we generated and analyzed the corresponding TNC-fusion proteins (Flag-TNChCD95L(137-281) and Flag-TNC-hTRAIL(95-291), Figure 7a ). Cross-linking experiments with BS 3 and gel filtration analysis indicated that Flag-TNC-hCD95L(137-281) and Flag-TNC-hTRAIL(95-291) assemble into trimers ( Figure 4 and Table 1 ). FACS analysis further showed that both TNC-fusion proteins were somewhat more efficient (3-10-fold) than their TNC-less counterparts in receptor binding (Figure 7b ). Flag-TNC-hCD95L(137-281) showed a 5-to 30 fold lower ED50 value for induction of cell death, compared to Flag-hCD95L(137-281). Non-crosslinked Flag-TNC-hTRAIL (95-291) showed regularly approximately fivefold lower ED 50 With respect to the capability to induce cell death after cross-linking, however, the differences were much more pronounced with 100-to 200-fold lower ED 50 values for Flag-TNC-hTRAIL(95-291) (Figure 7c ). The need for ligand cross-linking to activate human TRAILR2 is also required for Figure 7 Continued is not clear yet, but could be related to two obvious points. First, the importance of the TNC domain for receptor binding could be receptor specific. As KB and L929 cells express not only the TRAIL death receptors, but also the TRAIL decoy receptors, it cannot be ruled out that latter binds quite well to the TNC-less TRAIL variant masking a more pronounced effect on binding to the TRAIL death receptors. Furthermore, in the human system TRAILR1 and TRAILR2, which are differentially dependent on ligand cross-linking for activation, are also differentially regulated by TRAILR4. 19, 20 Second, the transformation of receptor occupancy by ligand into DISC formation and further to activation of apoptotic caspases could be non-linear and receptor-specific. Taken together, fusion with the TNC domain did not overcome the requirement of hCD95L and hTRAIL for secondary cross-linking to become properly active ( Figure  7c and d) . This is in agreement with the fact that the TNC domain does not mediate secondary aggregation of ligand trimers. Thus, the introduction of a TNC domain appears to be a broadly applicable option to generate recombinant soluble ligands of the TNF family with superior activity.
Materials and Methods
Plasmids and cell lines. All expression plasmids encoding the proteins summarized in Figure 1 were constructed based on the PS435 plasmid, which is a modification of pCR3 (Invitrogen, Karlsruhe, Germany) encoding N-terminally Flagtagged TRAILR2 with an immunoglobulin signal peptide. 21 PS435 was a kind gift from Pascal Schneider (University of Lausanne, Epalinges, Switzerland). To obtain the pCR3-derived expression plasmids encoding the various TRAIL and CD95L fusion proteins, the indicated domains of hTRAIL (U37518), mTRAIL (NM_009425), hCD95L (U11821) and murine CD95L (NM_010177) were amplified with primers having 5 0 overhangs containing a EcoR1 site and 3 0 overhangs containing a Xba1 or Xho1 site and used to replace the TRAILR2 part of PS435. To obtain expression plasmids encoding the TNC counterparts of the resulting Flag-tagged TRAIL and CD95L variants, the Flag tag-encoding DNA fragment was removed using the flanking BamH1 and EcoR1 sites and replaced by a corresponding amplicon encoding the Flag tag and aa 110-139 of chicken TNC (M23121). To obtain the expression plasmids, encoding Flag-L-mCD95L(137-279) and Flag-L-mTRAIL(99-291), the cDNA part encoding the TNC domain was replaced by a linker encoding a similar number of amino acids. MBL2-mCD95 cells are a kind gift from JP Medema (Academic Medical Center, Amsterdam, Netherlands) and have been described elsewhere. 22 Production and purification of recombinant proteins. The different plasmids encoding the various TRAIL and CD95L variants were transfected in HEK293 by electroporation. A total of 40 Â 10 6 HEK293 cells, suspended in 1 ml RPMI supplemented with 10% FCS, were electroporated (4 mm cuvette, 250 V, 1800 mF, maximal resistance) with 30 mg of plasmid DNA. Cells were recovered overnight in 15 cm dishes with RPMI/10% FCS. The next day, medium was changed with low serum medium (0.5% FCS) and supernatants were collected after additional 3-4 days. Supernatants were concentrated by dialysis on PEG35000 and the recombinant proteins were purified by affinity chromatography using an antiFlag mAb M2 agarose column (Sigma). The bound proteins were eluted with 100 mg/ml Flag peptide (Sigma) and dialyzed against PBS to remove the majority of the Flag peptide. Purified proteins were quantified by BCA (Pierce) and/or by comparison with a flag-tagged protein standard by Western blotting. Concentrations of non-tagged variants of mTRAIL and CD95L were determined by Western blot comparison using rat anti-mTRAIL mAb N2B2, a kind gift from Professor Yagita (Juntendo University School of Medicine, Tokyo, Japan), and goat anti-hCD95L IgG (RD Systems, Wiesbaden, Germany) mAbs samples with their Flag-tagged counterparts at known concentrations. Fc-hTRAIL and Fc-hCD95L are fusion proteins containing the constant region of human IgG1 and the THD of hTRAIL and hCD95L, respectively. Both proteins were kindly prepared by Victoria Schäfer (University of Wuerzburg, Germany).
Flow cytometry with recombinant TRAIL and CD95L variants. Cells were incubated for 30 min at 41C with the indicated concentration of the various variants of CD95L or TRAIL. After washing the cells three times with PBS containing 0.5% bovine serum albumin (BSA; Sigma), cells were incubated with 5 mg/ml anti-Flag mAb M2 (Sigma) for 30 min at 41C. After washing three times with PBS/BSA the cell-bound fusion protein-antibody complexes were detected using PE-conjugated goat anti-mouse IgG (whole molecule) IgG. 3 /well) were cultured in 100 ml of culture medium in 96-well plates. The Next day, cells were treated in triplicates with the indicated concentrations of the various variants of CD95L or TRAIL in the presence and absence of the crosslinking 0.5 mg/ml anti-Flag mAb M2. Holler et al. 7 have previously shown that antiFlag-induced multimerization becomes suboptimal at higher ligand concentrations. In our experiments, this becomes evident especially when TRAIL variants were used. We therefore used, in some experiments with TRAIL proteins, 3 mg/ml of anti-Flag M2 for cross-linking to induce apoptosis. After 20 h, cell viability was determined by crystal violet staining (KB, L929, MBL2-CD95) or the MTT assay (Jurkat). To sensitize KB and L929 cells for induction of cell death, these cells were stimulated in the presence of 2.5 mg/ml cycloheximide (Sigma).
Silver staining. Approximately 250 ng of the affinity-purified proteins was separated by 16% SDS-PAGE using reducing and non-reducing Laemmli sample buffer. After incubation twice with fixer (40% methanol, 12% acetic acid) for 30 min and washing twice with 30% ethanol, gels were treated with 0.02% (w/v) sodium thiosulfate for 1 min. After three times washing for 30 s in distilled H 2 O and incubation for 20 min in 0.2% (w/v) silver nitrate solution freshly supplemented with formaldehyde (1 : 333), gels were washed again in ddH 2 O (three times for 1 min) and were finally developed with 6% (w/v) sodium carbonate freshly supplemented with formaldehyde (1 : 500) and 0.0004% (w/v) sodium thiosulfate. When the desired signal intensity was achieved the developer was discarded and the reaction was stopped with 5% acetic acid.
Gel filtration. Protein samples were applied either to a BioSep-SEC-S2000 (300 Â 7.8) column or to a BioSep-SEC-S3000 (300 Â 7.8) column (Phenomenex, Aschaffenburg, Germany) equilibrated in PBS and eluted at a flow rate of 0.5 ml/min. DISC analysis. DISC analysis with Flag-TNC-hTRAIL(95-291) and FlaghTRAIL(95-291) were performed as described recently elsewhere. 23 Antibodies used to detect FADD, FLIP, TRAILR1, and caspase-8 were purchased from BD (Heidelberg, Germany; FADD) and Axxora (Grünberg, Germany; TRAILR1 and FLIP) or was a kind gift from K Schulze-Osthoff (University of Düsseldorf, Germany; anti-caspase-8 mAb).
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Surface plasmon resonance analysis of CD95L-CD95 interaction. Dissociation constants (K D ) for the binding of Flag-hCD95L(137-281), Flag-mCD95L(137-279) and Flag-TNC-mCD95L(137-279) to an immobilized fusion protein of hIgG1 and the extracellular domain of human CD95 (Fc-CD95) were calculated from surface plasmon resonance measurements (BIAcore 2000, Pharmacia). Fc-CD95 was biotinylated and coupled with 1 mg/ml to the surface of a streptavidin-coated sensor chip (Pharmacia) as described elsewhere. 24 Sensorgrams were recorded for binding of the various ligands at concentrations ranging from 2 (hCD95L) or 5 nM (mCD95L variants) to 1000 and 5000 nM, respectively. The kinetic constants (k d and k a ) were determined using a 1 : 1 binding model and the software supplied by the manufacturer and were used to calculate the dissociation constant.
